Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 14 December 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Post-transplant lymphoproliferative risk in pancreas recipients

Post-transplant lymphoproliferative in pancreas recipients has a worse prognosis than in other transplant recipients, and these immunosuppressed patients, who often face multiple transplants, may be at greater risk, reports the latest Transplantation.

News image

fiogf49gjkf04

Post-transplant lymphoproliferative disorder is a rare, serious complication of transplantation.

The characteristics and associations of this disease in pancreas recipients have not been extensively studied.

Dr Steven Paraskevas and colleagues performed 787 pancreas and 569 kidney-pancreas transplants from 1988 to 2002 at their institution.

The research team reported that 18 pancreas recipients developed polymorphic posttransplant lymphoproliferative disorder or malignant lymphoma.

Data on clinical course, organ involvement, molecular characteristics was compiled from the institutional transplant database

Cytomegalovirus infection may play an antecedent role
Transplantation

The researchers also compiled data on and association with immunosuppression and recent cytomegalovirus infection.

Patient survival was compared to recipients of liver and kidney transplants at the same center by using Kaplan-Meier analysis.

The researchers found that the 5-year cumulative incidence of posttransplant lymphoproliferative in simultaneous pancreas-kidney recipients was 3%.

The 5-year cumulative incidence of post-transplant lymphoproliferative in pancreas after kidney recipients was 1.2%.

In pancreas transplant alone recipients, the 5-year cumulative incidence of the disease was 1%.

The team noticed a higher, but not significant, cumulative incidence in the more recent era since 1995.

Post-transplant lymphoproliferative in pancreas recipients carried a worse prognosis than in liver or kidney for recipients B-cell.

The researchers also observed that Post-transplant lymphoproliferative had a worse prognosis with early-onset, and Epstein Barr virus-positive lesions.

Posttransplant lymphoproliferative was more aggressive in pancreas recipients, with a higher stage at presentation and a trend to more bone marrow involvement.

The research team noted a tendency toward association with recent cytomegalovirus infection.

Since 1995, the team observed that post-transplant lymphoproliferative recipients have had a lower exposure to antilymphocyte preparations.

Dr Paraskevas' team concludes, “Posttransplant lymphoproliferative in pancreas recipients remains a rare but aggressive disease, and carries a worse prognosis in comparison to other transplant recipients.”

“These heavily immunosuppressed patients, who often face multiple transplants, may be at greater risk; cytomegalovirus infection may play an antecedent role.”

Transpl 2005: 80(5) 613-22
22 September 2005

Go to top of page Email this page Email this page to a colleague

 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 14 December 2017 
Reliability of the IBD index
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 13 December 2017 
Management of abnormal liver blood tests
 13 December 2017 
Tryptophan metabolism and IBD activity
 13 December 2017 
Disease severity in NAFLD
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 05 December 2017 
Childhood obesity into adulthood
 05 December 2017 
CT imaging for acute diverticulitis
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 04 December 2017 
Neoadjuvant chemoradiation for locally advanced rectal cancer
 04 December 2017 
Physical activity and Barrett’s esophagus
 04 December 2017 
Alcohol abstinence and alcoholic hepatitis
 01 December 2017 
Therapeutic drug monitoring in IBD
 01 December 2017 
Insulin therapy and liver cancer among diabetics
 01 December 2017 
Family burden of pediatric Crohn's in the USA
 30 November 2017 
Anastomotic leak after repeat intestinal resection in Crohn’s
 30 November 2017 
Oral capsule– vs colonoscopy-delivered fecal microbiota transplant
 30 November 2017 
Sessile serrated polyps and H. pylori in the USA
 29 November 2017 
Medical cannabinoid legalization policy and vomiting
 29 November 2017 
Predicting mortality after colectomy for C. diff
 29 November 2017 
Obesity and cancer risk
 28 November 2017 
Celiac disease screening in adult first-degree relatives
 28 November 2017 
Electronic health record alert in primary care in Hep C
 28 November 2017 
Surgical treatment delays and colon cancer survival
 27 November 2017 
Questionnaire fore chronic constipation
 27 November 2017 
Challenges in measuring the affordability of US health care
 27 November 2017 
Early readmission in IBD patients
 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Predicting microscopic colitis
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us